Research Use Only (RUO) Disclaimer: CJC-1295 and Ipamorelin are research peptides not approved by the FDA, EMA, or any equivalent regulatory body for human therapeutic use. All information in this article is for educational and scientific research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Consult a licensed healthcare provider before any human use.

CJC-1295 + Ipamorelin Stack: Complete Research Protocol Guide 2026

The CJC-1295 + Ipamorelin combination is the most studied growth hormone secretagogue stack in the peptide research literature. It pairs two fundamentally different peptides — a GHRH receptor agonist and a ghrelin receptor agonist — that activate parallel intracellular signaling cascades in the same anterior pituitary cell, producing a GH pulse that is consistently characterized as synergistic rather than merely additive.

This guide covers the mechanistic rationale for the combination, what the research literature reports about protocols and dosing, the critical decision between CJC-1295 with and without DAC, the triple-stack extension with MK-677, storage and reconstitution methodology, and a comparison with alternative GH secretagogue stacks including Sermorelin- and Tesamorelin-based protocols.

For individual compound profiles, see the dedicated CJC-1295 research profile and Ipamorelin research profile. To calculate doses for specific vial concentrations, use the peptide dosing calculator or the stack builder.

Why Stack CJC-1295 + Ipamorelin? The Dual-Receptor Mechanism

Growth hormone secretion from anterior pituitary somatotrophs is governed by two competing hypothalamic signals: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which suppresses it. Within the pituitary, two independent receptor systems transduce these inputs:

• GHRH receptor (GHRH-R): Coupled to Gαs proteins, its activation raises intracellular cAMP via adenylyl cyclase and activates protein kinase A (PKA). PKA phosphorylates transcription factors that increase GH gene expression and prime secretory vesicles for fusion at the plasma membrane.
• GHS-R1a (ghrelin receptor): Coupled to Gαq proteins, its activation recruits phospholipase C (PLC), which generates IP₃ and diacylglycerol (DAG). IP₃ triggers calcium release from the endoplasmic reticulum, and this calcium surge directly drives secretory vesicle exocytosis. GHS-R1a activation also suppresses somatostatin release from hypothalamic neurons, further amplifying the GH-permissive environment.

CJC-1295 is a synthetic analog of GHRH(1-29) that acts on GHRH-R. Ipamorelin is a pentapeptide synthetic GHRP that acts on GHS-R1a. Because these two receptors use completely different intracellular second-messenger systems — cAMP/PKA versus calcium/PLC — their downstream signals are independent. When both receptors are activated simultaneously, their effects at the level of GH vesicle exocytosis are additive at minimum, and the literature frequently characterizes the combined pulse as synergistic.

The synergistic nature of GHRH + GHRP co-administration was established in foundational human pharmacology studies by Bowers and colleagues in the early 1990s, who demonstrated that GHRH + GHRP-6 co-infusion produced GH pulse amplitudes significantly greater than either compound alone (interactive effect P<0.01 in controlled infusion studies). Later work by Cunha and Mayo (2002, Endocrinology) characterized the molecular basis: active GHS-R1a signaling potentiates GHRH-R signaling on the same somatotroph cell, suggesting the synergy is not merely additive but involves cross-receptor amplification.

Quantitatively, research protocols consistently describe the combined GH pulse as 3–5 times larger than either peptide alone at equivalent doses — a finding that has made this pair the dominant multi-peptide GH stack across preclinical and translational research settings.

Why Ipamorelin Specifically?

While the GHRH + GHRP synergy holds for multiple GHRP-class peptides (GHRP-6, GHRP-2, hexarelin), Ipamorelin became the preferred research partner for CJC-1295 because of its exceptional selectivity profile. The landmark 1998 characterization paper by Raun et al. (European Journal of Endocrinology) demonstrated that Ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold higher than the ED₅₀ for GH release. Prolactin was similarly unaffected.

This selectivity — absent in GHRP-6, GHRP-2, and hexarelin — allows researchers to study GH pathway activation in isolation without the confounding influence of simultaneous HPA axis activation. For investigations where cortisol or prolactin elevation would complicate the data, Ipamorelin is the methodologically sound choice.

Research Background on the Combination

Direct human RCT data specifically testing the CJC-1295 (no DAC) + Ipamorelin combination at the doses common in research planning protocols remains limited. The mechanistic foundation rests on several well-established bodies of evidence that, taken together, provide strong scientific grounding:

1. GHRH + GHRP synergy literature: Multiple controlled human studies have confirmed synergistic GH release when GHRH analogs and GHRP-class peptides are co-administered. Studies using GHRP-2 + GHRH, GHRP-6 + GHRH, and hexarelin + GHRH in human volunteers consistently show amplified GH release beyond what either peptide produces individually.
2. CJC-1295 (with DAC) clinical data: A 2006 study in The Journal of Clinical Endocrinology & Metabolism (Teichman et al.) demonstrated dose-dependent increases in mean plasma GH of 2–10-fold and IGF-1 increases of 1.5–3-fold with CJC-1295 DAC monotherapy in healthy adults. This establishes the potency of the CJC-1295 molecule itself.
3. Ipamorelin pharmacology: Raun et al. (1998) characterized Ipamorelin's GH-releasing potency and selectivity profile in rodent and primate models, establishing the dose-response relationship and confirming the absence of ACTH/cortisol co-stimulation that makes it methodologically superior to earlier GHRPs.
4. Pre-blended commercial availability: The widespread availability of pre-blended CJC-1295/Ipamorelin products from licensed compounding pharmacies and research suppliers reflects researcher demand and implied translational interest. These blends typically combine equal quantities of each peptide in a single vial.

The FDA's October 2024 Pharmacy Compounding Advisory Committee (PCAC) review documented the limited direct human RCT data on this specific combination at research-planning doses, while acknowledging the mechanistic rationale. Both compounds remain available through licensed 503A compounding pharmacies on physician prescription, and both remain on the WADA Prohibited List (S2 category: GH secretagogues) for competitive athletes.

Research Protocols: Saturation Doses, Pulse Timing, and Frequency

The Saturation Dose Concept

Both Ipamorelin and CJC-1295 (no DAC) exhibit a saturation dose at the level of pituitary receptor signaling. Beyond this dose, additional peptide does not proportionally increase GH output because receptor occupancy is approaching maximum. The saturation dose for both compounds is widely cited in the research pharmacology literature at approximately 100 mcg per injection.

This saturation threshold has important practical implications for protocol design: doses above 200–300 mcg per injection are not expected to produce meaningfully larger GH pulses, making higher doses primarily a way to extend duration of receptor occupancy rather than increase peak amplitude. Most published and reported research protocols therefore cluster in the 100–300 mcg range for each compound.

Common Research Protocol Parameters

Based on the available literature and reported research protocols, the following parameters characterize the most commonly studied CJC-1295 (no DAC) + Ipamorelin administration patterns:

Timing Rationale: Why the Fasted State Matters

GH secretion is physiologically suppressed by elevated blood glucose and insulin. Both glucose and insulin directly inhibit GHRH signaling and reduce somatotroph responsiveness to secretagogue stimulation. Research protocols therefore consistently specify administration in the fasted state — typically 60–90 minutes after the last meal and at least 30 minutes before the next — to maximize GH pulse amplitude.

Pre-sleep administration is used in many protocols because it coincides with the largest naturally occurring GH pulse of the circadian cycle, which occurs shortly after sleep onset in stage 3 slow-wave sleep. Augmenting this endogenous pulse pharmacologically is one rationale for the common bedtime administration schedule.

Single Daily vs. Multiple Daily Administrations

Single daily protocols (one injection before sleep) represent a lower-intensity approach that augments the nocturnal GH pulse while minimizing disruption to the natural 24-hour GH pulsatility pattern. This approach is reported in studies focused on IGF-1 elevation and recovery-related endpoints.

Multiple daily administration protocols (typically 2–3 injections distributed across the day — morning fasted, pre-exercise, and pre-sleep) are designed to maximize cumulative GH exposure across the circadian cycle. These higher-intensity protocols are associated with more pronounced IGF-1 elevation and are used in studies examining body composition and metabolic endpoints over 8–16 week periods.

CJC-1295 With DAC vs. Without DAC in the Stack

One of the most consequential protocol decisions in CJC-1295 + Ipamorelin research is selecting between the two forms of CJC-1295. Despite sharing the same base name, they have fundamentally different pharmacokinetic profiles that produce different types of GH signaling.

CJC-1295 Without DAC (Modified GRF 1-29)

CJC-1295 without DAC incorporates four amino acid substitutions (positions 2, 8, 15, and 27) that confer resistance to dipeptidyl aminopeptidase IV (DPP-IV) cleavage, extending the plasma half-life from native GHRH's ~7 minutes to approximately 30 minutes to 2 hours. This produces a defined GH pulse when combined with Ipamorelin — a clear peak in GH concentration that then resolves as the peptide is cleared.

Characteristics in the stack:

• Produces discrete, measurable GH pulses that closely mimic physiological pulsatile secretion
• Requires administration with each Ipamorelin injection to maintain the synergistic effect
• Better suited for protocols studying pulsatile GH dynamics, timing effects, and physiological GH patterns
• Lower per-milligram cost relative to DAC variant
• More commonly available in pre-blended combination vials with Ipamorelin

CJC-1295 With DAC

The addition of the Drug Affinity Complex (DAC) — a maleimide-containing lysine derivative that covalently binds to circulating albumin — transforms the pharmacokinetic profile dramatically. Albumin-bound CJC-1295 DAC has a plasma half-life of approximately 6–8 days, as confirmed in the 2006 Teichman et al. clinical study, which documented GH increases lasting 6+ days and IGF-1 elevation persisting 9–11 days after a single injection.

Implications for the stack:

• Once- or twice-weekly CJC-1295 DAC administration can maintain a continuous GH-permissive background, while Ipamorelin is administered daily (1–3×) to generate pulsatile GH spikes on top of this tonic baseline
• The result is a dual-profile: tonic GH elevation from the DAC form plus acute pulsatile spikes from Ipamorelin
• Continuous GH elevation differs from physiological pulsatility — a confounding factor in studies where GH pulse pattern matters
• Higher per-milligram cost than no-DAC form; less commonly available in pre-blended vials
• Some researchers prefer this approach for its convenience (less frequent injection of the GHRH component)

Stack Configuration Summary

Adding MK-677: The Triple Stack Research Protocol

MK-677 (Ibutamoren) is an orally bioavailable, non-peptidic GH secretagogue that acts as a potent and selective agonist of GHS-R1a — the same ghrelin receptor targeted by Ipamorelin, but via a structurally distinct small molecule. Its ~24-hour plasma half-life produces sustained rather than pulsatile GH and IGF-1 elevation from once-daily oral administration.

Mechanistic Rationale for the Triple Stack

The CJC-1295 + Ipamorelin + MK-677 triple stack is designed to achieve comprehensive GH axis stimulation across different temporal windows:

• CJC-1295 (no DAC): Primes and amplifies GH vesicle pools via GHRH-R/cAMP/PKA signaling
• Ipamorelin: Generates acute GH pulse spikes via GHS-R1a/calcium and suppresses somatostatin; administered 1–3× daily
• MK-677: Provides a sustained 24-hour GH and IGF-1 baseline elevation via continuous GHS-R1a occupancy from once-daily oral dosing

The theoretical result is a three-layer GH profile: a tonic GHS-R1a-mediated baseline (MK-677), discrete GHRH-amplified spikes (CJC-1295 + Ipamorelin injections), with somatostatin suppression reinforced by both GHS-R1a agonists.

Research Considerations for the Triple Stack

Because MK-677 and Ipamorelin both act on GHS-R1a, researchers should consider receptor saturation dynamics. When MK-677 provides continuous baseline GHS-R1a occupancy, the incremental GH pulse from Ipamorelin co-administration may be attenuated relative to Ipamorelin alone on a clean GHS-R1a background. The practical significance of this interaction in vivo remains an area of ongoing investigation.

IGF-1 monitoring is particularly important in triple-stack protocols given the additive potential of three GH-stimulating agents. Baseline and periodic IGF-1 measurement is considered standard methodology in responsible research with this combination.

MK-677's known metabolic effects — particularly insulin resistance and mild fluid retention at higher doses — are relevant confounders in any study examining metabolic endpoints. Fasting glucose and insulin sensitivity monitoring are methodologically appropriate in triple-stack studies of extended duration.

MK-677 Sourcing and Pricing (2026)

MK-677 is available from research suppliers in both powder (10 mg vials) and oral capsule formats. Current peptides.so listing data shows research-grade MK-677 ranging from approximately $42 to $80 per 10 mg vial across suppliers. Oral capsule formulations (typically 10–12.5 mg per capsule, 60 count) range from $47 to $79. For triple-stack protocols, the oral convenience of MK-677 is operationally useful compared to the injectable CJC-1295 and Ipamorelin components.

Storage and Reconstitution for the Stack

Lyophilized (Pre-Reconstitution) Storage

Both CJC-1295 and Ipamorelin are supplied as lyophilized (freeze-dried) white powder in sterile vials, either as separate vials or in pre-blended combination vials containing equal quantities of each peptide. Storage requirements before reconstitution:

• Temperature: −20°C (standard laboratory freezer) for long-term storage; short-term (2–4 weeks) at 2–8°C refrigerator temperature is generally acceptable
• Protect from: Light, moisture, and temperature fluctuations
• Shelf life: Typically 2+ years at −20°C when properly stored; manufacturer certificates of analysis specify peptide purity at time of manufacture

Reconstitution Protocol

Bacteriostatic water (BAC water, containing 0.9% benzyl alcohol) is the standard reconstitution solvent for research peptide vials intended for multi-dose use. The benzyl alcohol acts as a bacteriostatic preservative between needle accesses, and at standard concentrations it does not react with or degrade CJC-1295 or Ipamorelin peptide bonds under normal pH and temperature conditions.

Step-by-step reconstitution for a standard 5 mg/5 mg blend vial:

1. Allow the lyophilized vial and BAC water vial to reach room temperature (approximately 20–25°C)
2. Wipe both rubber stoppers with 70% isopropyl alcohol; air dry for 10 seconds
3. Draw the desired volume of BAC water into a sterile syringe (2 mL for a 5 mg/5 mg vial yields 1000 mcg/mL per peptide per mL; smaller volumes yield higher concentrations)
4. Direct the BAC water flow slowly down the inner glass wall of the peptide vial — never inject directly onto the lyophilized powder, as this can cause aggregation
5. Allow the powder to dissolve by gentle swirling; do not shake or vortex
6. Label the vial with reconstitution date and concentration

Post-Reconstitution Storage

• Storage temperature: 2–8°C (standard refrigerator); do not freeze reconstituted peptide solutions
• Stability window: Reconstituted solutions prepared with BAC water are stable for approximately 28 days at 2–8°C; sterile water (no preservative) solutions should be used within 72 hours
• Avoid: Temperature excursions above 25°C; a single 8-hour excursion to 25°C has been reported to reduce peptide potency by 30–50% in stability studies
• Location: Store on interior refrigerator shelves, not in the door compartment where temperature fluctuates with each opening
• Inspection: Prior to each use, visually inspect for cloudiness, particulate matter, or discoloration; discard any vial with visible contamination

Comparison: CJC-1295/Ipamorelin vs. Alternative GH Secretagogue Stacks

CJC-1295/Ipamorelin vs. Sermorelin Monotherapy

Sermorelin is a truncated GHRH analog (GHRH 1–29 amide) with a plasma half-life of approximately 10–12 minutes. As a monotherapy, it produces brief, sharp GH pulses but lacks the dual-receptor mechanism that makes the CJC-1295 + Ipamorelin combination uniquely powerful.

Sermorelin's discontinued FDA approval (withdrawn by manufacturer in 2008, though the compound remains available through compounding pharmacies) provides it with a larger clinical safety dataset than CJC-1295. However, for research applications aimed at maximizing GH output, the dual-pathway stack consistently outperforms Sermorelin monotherapy.

A Sermorelin + Ipamorelin stack is a direct analog of the CJC-1295 + Ipamorelin combination — replacing the longer-acting GHRH component with Sermorelin's shorter half-life version. This combination retains the dual-pathway synergy while using the most extensively studied GHRH peptide, though it requires more frequent administration due to Sermorelin's rapid clearance.

CJC-1295/Ipamorelin vs. Tesamorelin-Based Stacks

Tesamorelin occupies a unique position in the GH secretagogue landscape as the only FDA-approved compound in this class, marketed as Egrifta for HIV-associated lipodystrophy. Phase 3 clinical trial data documents 15–18% visceral fat reduction over 26 weeks — the most rigorously validated outcome data for any GHRH analog.

For researchers requiring regulatory-grade clinical evidence, Tesamorelin provides the strongest validation. For researchers studying dual-pathway GH amplification, the CJC-1295 + Ipamorelin combination provides the mechanistically more comprehensive approach. Tesamorelin + Ipamorelin stacks combine the FDA-approved GHRH backbone with the clean selectivity of Ipamorelin and merit consideration for translational research designs.

CJC-1295/Ipamorelin vs. Hexarelin-Based Stacks

Hexarelin is a more potent GHS-R1a agonist than Ipamorelin but sacrifices its primary advantage: selectivity. Hexarelin produces significant cortisol and prolactin elevation — effects that confound any study examining GH-specific endpoints in isolation. For pure GH-pathway research without HPA axis interference, Ipamorelin remains methodologically superior. Hexarelin's potency may be an advantage in specific protocols where absolute GH output is the primary variable and cortisol/prolactin confounding is manageable.

Supplier and Sourcing Considerations

Researchers sourcing CJC-1295 + Ipamorelin have two primary options: separate individual vials or pre-blended combination vials. Current peptides.so listing data documents the following pricing landscape across verified suppliers (July 2026):

Pre-Blended CJC-1295 + Ipamorelin Vials

Pre-blended vials combining both peptides in equal concentrations are widely available and represent the most cost-efficient sourcing approach for researchers using the combination. Pricing for 5 mg/5 mg blend vials currently ranges from approximately $32 to $100 across suppliers on peptides.so, with most reputable options in the $40–$75 range. Larger combination vials (10 mg/10 mg) run $90–$100.

Representative pricing from current supplier listings:

• Buy Peptides USA — CJC 1295 no DAC / Ipamorelin blend: $31.99
• Pure Lab Peptides — $39.99–$59.99 (multiple sizes)
• Genesis Peptides — $40
• Ameano Peptides — $41
• Welli Labs — $44.99
• Platinum Lion Peptides — $45 ($39.99 discounted)
• Glacier Aminos — $49.99–$54.99
• Pepvida Labs — $56 ($43 discounted)
• Biolongevity Labs — $99.97 (10 mg/10 mg vial)

Separate CJC-1295 Vials (With DAC)

Researchers running the long-acting hybrid stack (CJC-1295 DAC weekly + Ipamorelin daily) need to source the DAC variant separately, as it is rarely available in pre-blended combination format. Peptide Supply Group and Genesis Peptides list CJC-1295 with DAC at approximately $20–$50 per 5 mg vial.

What to Look For in a Research Supplier

Key quality indicators for research peptide suppliers include: Certificate of Analysis (CoA) from an independent third-party laboratory (HPLC purity and mass spectrometry verification), clear documentation of peptide sequence and molecular weight, appropriate labeling as Research Use Only (RUO), and transparent batch-level testing records. The stack builder tool allows comparison of verified supplier options for this combination.

See the Peptide Stack Buying Guide for detailed supplier evaluation criteria and cost-optimization strategies for multi-peptide research orders.

Internal Links for Deeper Research

This stacking guide is part of a broader research library. For compound-specific detail:

• CJC-1295 peptide profile and supplier comparison
• Ipamorelin peptide profile and supplier comparison
• CJC-1295 DAC detailed research profile
• Ipamorelin complete research profile
• MK-677 research profile
• CJC-1295 vs Ipamorelin comparison guide
• GHRH Analogs Compared: Sermorelin, CJC-1295, Tesamorelin
• GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin
• Peptide dosing calculator
• Stack builder

Key Takeaways for Researchers

• The CJC-1295 + Ipamorelin combination produces synergistic GH release (3–5× greater than either compound alone) by simultaneously activating the independent GHRH-R/cAMP and GHS-R1a/calcium signaling pathways in anterior pituitary somatotrophs
• Ipamorelin is preferred over earlier GHRPs (GHRP-2, GHRP-6, hexarelin) as the stack partner because it achieves GHS-R1a activation without ACTH/cortisol or prolactin co-stimulation, preserving experimental isolation of the GH pathway
• The DAC vs. no-DAC selection determines whether the GH profile is pulsatile (no DAC, administered with each Ipamorelin injection) or tonic-plus-pulsatile (DAC weekly + Ipamorelin daily)
• The saturation dose for both compounds is approximately 100 mcg per injection; doses above 200–300 mcg do not proportionally increase peak GH amplitude
• Adding MK-677 creates a triple-stack with sustained 24-hour GHS-R1a background activation layered below the pulsatile CJC/Ipamorelin injections; receptor competition between Ipamorelin and MK-677 at GHS-R1a is a relevant experimental consideration
• Pre-blended CJC-1295 (no DAC) + Ipamorelin vials are widely available from $32–$100, making this one of the most cost-accessible dual-peptide GH stacks in the research market
• No published human RCT has specifically tested this combination at the doses common in research protocols; the mechanistic rationale rests on strong GHRH + GHRP synergy data from related compound combinations

Research Use Only: CJC-1295 and Ipamorelin are not approved for human use by the FDA or any equivalent regulatory body. This article is intended exclusively for educational and research purposes. Nothing in this article constitutes medical advice. Researchers and clinicians should consult current regulatory guidance before designing human studies involving these compounds.